City

Clinical trials near Brno, Czechia

Active studies with a listed research site in Brno, Czechia.

18active studies

9recruiting now

21countries represented

243largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 3

A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

Urinary Incontinence,StressCondition

Orforglipron, PlaceboTreatment

Canada, China136 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07202884See eligibility →

Recruiting nowPhase 3

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

Ulcerative Colitis, Obesity or OverweightCondition

Mirikizumab, MirikizumabTreatment

Austria, Belgium187 locations

Eli Lilly and CompanySponsor

Updated 2026-09-04 · NCT06937086See eligibility →

Recruiting nowPhase 3

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

Crohn's Disease, Obesity or OverweightCondition

Mirikizumab, MirikizumabTreatment

Austria, Belgium183 locations

Eli Lilly and CompanySponsor

Updated 2026-09-04 · NCT06937099See eligibility →

Recruiting nowPhase 3

Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

Obesity, OverweightCondition

Ribupatide, PlaceboTreatment

Argentina, Australia104 locations

KaileraSponsor

Updated 2026-09-03 · NCT07284875See eligibility →

Recruiting nowPhase 3

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy

Obstructive Sleep ApneaCondition

Maridebart cafraglutide, PlaceboTreatment

Australia, Brazil57 locations

AmgenSponsor

Updated 2026-08-14 · NCT07226765See eligibility →

Recruiting nowPhase 3

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy

Obesity, Obstructive Sleep ApneaCondition

Maridebart cafraglutide, PlaceboTreatment

Australia, Brazil61 locations

AmgenSponsor

Updated 2026-08-04 · NCT07225686See eligibility →

Recruiting nowNot applicable

Non-invasive Brain Stimulation to Prepare the Patient for Bariatric Surgery (REBAS)

ObesityCondition

home-based tDCS stimulation, home-based tDCS stimulation - shamTreatment

Czechia2 locations

Masaryk UniversitySponsor

Updated 2025-03-13 · NCT06874309See eligibility →

Recruiting nowNot applicable

ENDOPLY System in Humans: a Pilot Study

ObesityCondition

ENDOPLY SystemTreatment

Czechia1 locations

ENDOPLYSponsor

Updated 2025-02-25 · NCT06292728See eligibility →

Recruiting nowPhase 2

Efficacy and Safety of KBP-336 in Obese Individuals with Osteoarthritis

Osteoarthritis in the Knee, ObesityCondition

KBP-336, PlaceboTreatment

Czechia, Denmark20 locations

KeyBioscience AGSponsor

Updated 2025-02-19 · NCT06833749See eligibility →

Opening soonPhase 3

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

Overweight, Prediabetic StateCondition

Orforglipron, PlaceboTreatment

Argentina, China179 locations

Eli Lilly and CompanySponsor

Updated 2026-08-31 · NCT07794579See eligibility →

Active, not recruitingPhase 3

Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity

Obesity and OverweightCondition

MET097, PlaceboTreatment

Bulgaria, Canada169 locations

PfizerSponsor

Updated 2026-09-04 · NCT07311850See eligibility →

Active, not recruitingPhase 3

A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes

Diabetes Mellitus, Type 2Condition

Semaglutide, Placebo (semaglutide)Treatment

Brazil, Bulgaria229 locations

Novo Nordisk A/SSponsor

Updated 2026-08-04 · NCT03811561See eligibility →

Active, not recruitingPhase 3

A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)

HypertensionCondition

Orforglipron, PlaceboTreatment

Argentina, China100 locations

Eli Lilly and CompanySponsor

Updated 2026-05-29 · NCT06948422See eligibility →

Active, not recruitingPhase 3

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1

Hypertension, Overweight or ObesityCondition

Orforglipron, PlaceboTreatment

Argentina, China99 locations

Eli Lilly and CompanySponsor

Updated 2026-05-29 · NCT06948435See eligibility →

Active, not recruitingPhase 3

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2

HypertensionCondition

Orforglipron, PlaceboTreatment

Argentina, China99 locations

Eli Lilly and CompanySponsor

Updated 2026-05-29 · NCT06952530See eligibility →

Active, not recruitingNot applicable

Development of Human Motor Skills and the Promotion of Motivation for Physical Activity

Physical Inactivity, Obesity & OverweightCondition

E-MOVE - Emotional Movement Program for Physical EducationTreatment

Czechia9 locations

Charles University, Czech RepublicSponsor

Updated 2026-03-20 · NCT07485270See eligibility →

Active, not recruitingPhase 3

Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

Type 2 Diabetes Mellitus (T2DM), Obesity, OverweightCondition

Maridebart cafraglutide, PlaceboTreatment

Argentina, Bulgaria187 locations

AmgenSponsor

Updated 2025-12-31 · NCT06858878See eligibility →

Active, not recruitingPhase 3

Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

ObesityCondition

Maridebart Cafraglutide, PlaceboTreatment

Argentina, Australia243 locations

AmgenSponsor

Updated 2025-10-20 · NCT06858839See eligibility →

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.

Clinical trials near Brno, Czechia

Current studies

Related cities